Drug Description in Trials / DrugBank / KEGG DRUG /

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.----1件: 276
2BGJ398 (also known as BBP-831)----1件: 276
3BMN 111----1件: 276
4C-type natriuretic peptide conjugated to a multi-arm polyethylene glycol carrier molecule through a cleavable linker1件: Polyethylene glycol1件: D03370 --1件: 276
5C-TYPE NATRIURETIC PEPTIDE CONJUGATED TO MULTI-ARM POLYETHYLENE GLYCOL CARRIER THROUGH A CLEAVABLE LINKER1件: Polyethylene glycol1件: D03370 --1件: 276
6Growth hormone1件: Somatotropin---14件: 2, 13, 19, 46, 78, 96, 107, 187, 191, 193, 195, 265, 276, 299
7Human Growth Hormone1件: Somatotropin---5件: 78, 187, 193, 265, 276
8INFIGRATINIB1件: Infigratinib1件: D11589 3件: FGFR1,
FGFR2,
FGFR3 💬		21件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬1件: 276
9Infigratinib 0.016 mg/kg1件: Infigratinib1件: D11589 3件: FGFR1,
FGFR2,
FGFR3 💬		21件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬1件: 276
10Infigratinib 0.032 mg/kg1件: Infigratinib1件: D11589 3件: FGFR1,
FGFR2,
FGFR3 💬		21件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬1件: 276
11Infigratinib 0.064 mg/kg1件: Infigratinib1件: D11589 3件: FGFR1,
FGFR2,
FGFR3 💬		21件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬1件: 276
12Infigratinib 0.128 mg/kg1件: Infigratinib1件: D11589 3件: FGFR1,
FGFR2,
FGFR3 💬		21件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬1件: 276
13Infigratinib 0.25 mg/kg1件: Infigratinib1件: D11589 3件: FGFR1,
FGFR2,
FGFR3 💬		21件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬1件: 276
14Infigratinib phosphate2件: Infigratinib,
Phosphate ion		1件: D11589 3件: FGFR1,
FGFR2,
FGFR3 💬		21件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬1件: 276
15Modified recombinant human c-type----1件: 276
16Modified recombinant human C-type natriuretic peptide----1件: 276
17MODIFIED RHCNP----1件: 276
18Natriuretic peptide----1件: 276
19Normal Saline----18件: 6, 13, 17, 22, 36, 46, 49, 60, 70, 94, 96, 210, 211, 226, 271, 276, 296, 299
20PF-07256472----1件: 276
21Phosphate1件: Phosphate ion---32件: 2, 3, 6, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 238, 256, 276, 283, 284, 285, 286, 299
22Placebo----28件: 3, 5, 6, 11, 13, 14, 37, 40, 46, 49, 50, 51, 53, 63, 66, 67, 79, 85, 86, 88, 96, 97, 140, 144, 149, 226, 271, 276
23Polyethylene glycol1件: Polyethylene glycol1件: D03370 --7件: 6, 78, 96, 97, 235, 276, 299
24Recifercept----1件: 276
25Recifercept (proposed INN)----1件: 276
26RECOMBINANT HUMAN GROWTH HORMONE1件: Somatotropin---4件: 78, 193, 265, 276
27Somatropin1件: Somatotropin---19件: 2, 3, 19, 46, 65, 74, 75, 78, 96, 107, 113, 187, 193, 195, 238, 265, 274, 276, 299
28TA-46----1件: 276
29TBD----5件: 19, 86, 90, 276, 299
30TransCon CNP----1件: 276
31TransCon CNP 3.9 mg CNP-38/vial----1件: 276
32Vorsoritide----1件: 276
33Vosoritide1件: Vosoritide1件: D11190 1件: NPR2 💬5件: Metabolic pathways, Oxytocin signaling pathway, Purine metabolism, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 276